نتایج جستجو برای: starting treatment dose
تعداد نتایج: 1692094 فیلتر نتایج به سال:
The RERF International Low-Dose Symposium was held on 5-6 December 2013 at the RERF campus in Hiroshima, Japan, to discuss the issues facing the Life Span Study (LSS) and other low-dose studies. Topics included the current status of low-dose risk detection, strategies for low-dose epidemiological and statistical research, methods to improve communication between epidemiologists and biologists, ...
The role of aspirin in women with infertility is controversial and the evidence is inconsistent; some studies have reported benefits in women undergoing IVF whilst others have not. An important gap in the literature was the question of when to start and when to stop aspirin and how long should aspirin be given for. In a 2007 systematic review on the effectiveness of aspirin on IVF outcomes invo...
<b><i>Background:</i></b> Neonatal thrombosis is a frequently encountered complication in neonatal intensive care unit. Dalteparin can be used to treat newborn infants. <b><i>Objectives:</i></b> In this study, we evaluate the current recommended starting dose of 129 ± 43 U/kg/24 h, hypothesizing that too low reach therapeutic anti-Xa levels. <b...
3.1: Treatment of the initial episode of SSNS 3.1.1: We recommend that corticosteroid therapy (prednisone or prednisolone)* be given for at least 12 weeks. (1B) 3.1.1.1: We recommend that oral prednisone be administered as a single daily dose (1B) starting at 60 mg/m/d or 2 mg/kg/d to a maximum 60 mg/d. (1D) 3.1.1.2: We recommend that daily oral prednisone be given for 4–6 weeks (1C) followed b...
Ten patients with congenital adrenal hyperplasia (three males, seven females; aged 12-29 years) had their usual glucocorticoid treatment changed to dexamethasone in three crossover dosage regimens. A starting dose of 5 micrograms/kg/day is suggested but as no one dose regimen resulted in adequate control the timing of the dose must be decided for each patient.
BACKGROUND Levothyroxine (LT4) and rifampin (RIF) are sometimes used together; however, no clinical studies have assessed the effects of these drugs on thyroid function or the need to adjust LT4 dose. METHODS We retrospectively reviewed the records of 71 Korean patients who started RIF during LT4 treatment. Clinically relevant cases that required dose adjustment according to the American Thyr...
IMPORTANCE Hyperkalemia is a potentially life-threatening condition predominantly seen in patients treated with renin-angiotensin-aldosterone system (RAAS) inhibitors with stage 3 or greater chronic kidney disease (CKD) who may also have diabetes, heart failure, or both. OBJECTIVES To select starting doses for a phase 3 study and to evaluate the long-term safety and efficacy of a potassium-bi...
BACKGROUND Polymyalgia rheumatica (PMR) treatment is based on low-dose glucocorticoids. Glucocorticoid-sparing agents have also been tested. Our objective was to systematically examine the peer-reviewed literature on PMR therapy, particularly the optimal glucocorticoid type, starting doses, and subsequent reduction regimens as well as glucocorticoid-sparing medications. METHODS We searched Co...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید